EP Patent

EP3038652B1 — Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases

Assigned to Novartis AG · Expires 2018-03-21 · 8y expired

What this patent protects

Patent listed against Livtencity.

Drugs covered by this patent

Patent Metadata

Patent number
EP3038652B1
Jurisdiction
EP
Classification
—
Expires
2018-03-21
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.